Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07365319 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
A Phase 2 study, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
NCT07365319: Recruiting Phase 2 study, sponsored by Eikon Therapeutics.
NCT07365319 is a Phase 2 study that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 750 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (464% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07365319, a Phase 2 study, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Primary Outcome
Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by BICR, or death due to any cause, whichever occurs first
Interventions
- DRUG Placebo
- DRUG Pembrolizumab (KEYTRUDA®)
- DRUG EIK1001
- DRUG Paclitaxel + Carboplatin
- DRUG Nab-paclitaxel + Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2040-12-31 |
| Phase | Phase 2 |
What NCT07365319 shows while recruiting
NCT07365319 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (464% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT07365319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07365319 about?
NCT07365319 is a clinical study titled "A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.". This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
What is the current status of trial NCT07365319?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2026-05-18. Estimated completion is 2040-12-31.
What interventions are being tested in trial NCT07365319?
The interventions under investigation include: Placebo (DRUG), Pembrolizumab (KEYTRUDA®) (DRUG), EIK1001 (DRUG), Paclitaxel + Carboplatin (DRUG), Nab-paclitaxel + Carboplatin (DRUG).
Who is sponsoring clinical trial NCT07365319?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07365319's enrollment target sits among peer trials
750 43rd of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI